Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


NCCN Readies Practitioners for Tapping the Potential of Biosimilars

April 1st 2016

While biosimilars have the potential to create competition and result in healthcare savings, the path to the marketplace has proven complex.

Dr. Zelenetz on the Role of Biosimilars in Cancer Care

March 31st 2016

Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.

Neratinib Application Delayed for HER2+ Breast Cancer

March 30th 2016

Puma Biotechnology announced that it plans to delay the submission of a new drug application until mid-2016 for neratinib as an extended adjuvant treatment for patients with HER2-positive early breast cancer following a trastuzumab-based regimen.

FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation

March 30th 2016

The FDA has approved defibrotide sodium as a treatment for severe hepatic veno-occlusive disease with associated kidney or lung abnormalities following hematopoietic stem cell transplantation.

Payers Still Denying Coverage Despite Clinical Trial Mandate

March 29th 2016

A mandate enacted after the 2010 Patient Protection and Affordable Care Act was supposed to improve health coverage for patients enrolled in clinical trials; however, nearly 63% of cancer centers and organizations that responded to a recent survey reported insurance denials of routine care costs associated with patient involvement in clinical trials during 2014.

The C Letter Word

March 28th 2016

Hematology/oncology fellowship coordinator, Theresa Marcus, reflects on what it was like to receive a diagnosis of cancer, experience recurrence, and later learn that she had finally become cancer-free with the help of her colleagues.

Does Physician-Physician Communication Matter?

March 28th 2016

Faisal Musa, MD, reviews the case of a patient with large granulocytic leukemia and discusses why collaborating with the patient’s pathologist was so important to her diagnosis.

Top 3 Must Do's to Prepare for Managed Care in 2016

March 24th 2016

Although there still are many unknowns, especially in light of this being an election year that will bring a new administration, it’s already very clear how the transition to value is affecting oncology practices.

Eribulin Liposarcoma Approval Advances Precision Medicine in Oncology

March 23rd 2016

George Demetri, MD, discusses the impact of the eribulin’s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Combined Biomarker Score Is Better Survival Predictor in Ovarian Cancer

March 20th 2016

Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.

Expanded Indication Sought for Ofatumumab in CLL

March 15th 2016

A supplemental new drug application has been submitted to the FDA for ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.

FDA Approves Crizotinib for ROS1-Positive NSCLC

March 11th 2016

The FDA has approved crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

FDA Accepts Application to Expand Pembrolizumab NSCLC Indication

March 7th 2016

The FDA has accepted a supplemental new drug application for pembrolizumab as a treatment for patients with advanced non–small cell lung cancer with PD-L1 expression on ≥1% of tumors cells.

FDA Approval Sought for Blinatumomab in Pediatric Acute Lymphoblastic Leukemia

March 3rd 2016

A supplemental biologics license application has been submitted to the FDA to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Alaskan Oncology Practices Operate by Remote

March 3rd 2016

Obtaining quality cancer care in Alaska is often difficult and expensive owing to the sparse highway network and the scattered nature of the state’s population of 736,000 people, who are spread out over more than a half-million square miles.

FDA Approves Everolimus for GI, Lung NETs

February 26th 2016

The FDA has approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal or lung neuroendocrine tumors.

FDA Approves Obinutuzumab for Follicular Lymphoma

February 26th 2016

The FDA approved obinutuzumab (Gazyva) plus bendamustine followed by obinutuzumab alone for the treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.

FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer

February 23rd 2016

The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.

Hatch-Waxman Act Keeps Generic Drugs Off the Market

February 22nd 2016

The Hatch Waxman Act, established in 1984 to promote lower cost generics production, is deeply flawed and has contributed to the maintenance of high drug prices.

FDA Grants Midostaurin Breakthrough Designation for AML

February 19th 2016

The FDA has granted midostaurin a breakthrough therapy designation as a potential treatment for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia.

NEXT PAGE
PREVIOUS PAGE